Research Topics
Genomes and GenesSpecies | Yutaka KondoSummaryAffiliation: Aichi Cancer Center Country: Japan Publications
| Collaborators
|
Detail Information
Publications
DNA methylation profiling in cancerYutaka Kondo
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
Expert Rev Mol Med 12:e23. 2010..In this review, the current key technologies available to assess genome-wide DNA methylation are introduced and the implications of DNA methylation profiling in human cancers are discussed...
Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cellsYutaka Kondo
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
PLoS ONE 3:e2037. 2008..Cancer cells are characterized by prominent epigenetic dysregulation, including histone modifications. However, the functional roles of the histone methyltransferases (HMT) in cancer remain unclear...- Epigenetic cross-talk between DNA methylation and histone modifications in human cancersYutaka Kondo
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
Yonsei Med J 50:455-63. 2009.... - Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cellsSachie Oi
Department of Neurosurgery, Nagoya University School of Medicine, Showa Ku, Nagoya, 466 8550, Japan
J Neurooncol 92:15-22. 2009..These findings not only shed light on an epigenetic immunotherapy, but also suggest that the silencing of NY-ESO-1 is mediated by histone modification... - The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for gliomaFumiharu Ohka
Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan
PLoS ONE 6:e23332. 2011..As a global DNA methylation marker, LINE-1 may be a promising marker in gliomas... - Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesotheliomaFutoshi Ishiguro
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
J Thorac Oncol 7:890-9. 2012..However, detailed characteristics of aberrant expression status of cell-adhesion molecules in malignant mesothelioma (MM) cells and their possible biological roles for MM malignancy remain poorly understood... - Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinomaKeiko Shinjo
Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
Carcinogenesis 33:1277-85. 2012..CIMP classification using our six-marker panel has implications for personalized medical strategies for lung cancer patients; in particular, DNA methylation inhibitor might be of therapeutic benefit to patients with CIMP-positive tumors... - Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinomaYasuhiro Goto
Divisions of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
Cancer Res 69:9073-82. 2009..Our findings show a characteristic epigenetic profile of MPM and uncover multiple distinct epigenetic abnormalities that lead to the silencing of tumor suppressor genes in MPM and could serve as diagnostic or prognostic targets... - Contribution of microRNA-1275 to Claudin11 protein suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cellsKeisuke Katsushima
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
J Biol Chem 287:27396-406. 2012..Given that inhibition of miR-1275 induces expression of oligodendroglial lineage proteins and suppresses tumor cell proliferation, this may be a potential therapeutic target for glioblastomas... - Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasisHai xing Ju
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
Am J Pathol 178:1835-46. 2011..In addition, most methylation status in stage IV CRCs seems to be established before metastasis... - The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human gliomaMasasuke Ohno
Department of Neurosurgery, Aichi Cancer Center Research Institute, Nagoya 466 8550, Japan
Mol Cancer Res 7:2022-30. 2009..These results highlight the importance of understanding the transcriptional regulation of the miRNAs involved in oncogenesis... - Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analysesYugo Kishida
Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, Aichi 466 8550, Japan
Carcinogenesis 33:436-41. 2012.... - YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylationToshihiko Yokoyama
Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
Carcinogenesis 29:2139-46. 2008..Future studies of transcriptional targets of YAP1 in MPMs may shed light on the molecular mechanisms of MPM development and lead to new therapeutic strategies... - Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumourYasuyuki Okamoto
Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
Gut 61:392-401. 2012..Our aim was to establish epigenetic profiles associated with the malignant transformation of GISTs... - Epigenetic aberrations and therapeutic implications in gliomasAtsushi Natsume
Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan
Cancer Sci 101:1331-6. 2010..Thus, epigenetic therapy may be a promising and potent treatment for human neoplasia... - Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomasWentao Gao
Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
Carcinogenesis 29:1901-10. 2008..Our global epigenome analysis reveals distinct patterns of methylation that are probably to represent different pathophysiologic processes in HCCs... - Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancerFutoshi Ishiguro
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
J Surg Res 179:24-32. 2013..However, the relationship between ALCAM expression and progression of non-small-cell lung cancer (NSCLC) has not been investigated. This study was designed to clarify the prognostic impact of ALCAM expression of NSCLC cells... - LATS2 is a tumor suppressor gene of malignant mesotheliomaHideki Murakami
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
Cancer Res 71:873-83. 2011..Thus, our results suggest that the inactivation of LATS2 is one of the key mechanisms for constitutive activation of YAP, which induces deregulation of MM cell proliferation... - Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascadeMakiko Fujii
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
Cell Cycle 11:3373-9. 2012..Furthermore, we demonstrated the functional importance of CTGF through the mouse studies and human histological analyses, which may elucidate the clinical features of MM with severe fibrosis in the thoracic cavity... - Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomasYugo Kishida
Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, 466 8550, Japan
Tumour Biol 33:373-81. 2012..The present results indicate that the quantification of MGMT methylation by bisulfite pyrosequencing represents its enzymatic activity and thus, its therapeutic responsiveness to alkylating agents... - TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growthMakiko Fujii
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Chikusa ku, Nagoya 464 8681, Japan
J Exp Med 209:479-94. 2012..These data suggest that CTGF is an important modulator of MM growth and pathology and represents a novel therapeutic target for this disease... - Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cellsKoji Kawaguchi
Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya, Japan
Carcinogenesis 30:1097-105. 2009.... - Activation of the PI3K-AKT pathway in human malignant mesothelioma cellsYutaro Suzuki
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
Mol Med Report 2:181-8. 2009..These findings suggest that AKT is frequently activated in MM cells, in part due to the downregulation of PTEN. Thus, the PI3K-AKT signaling pathway is a potential therapeutic target for MM... - Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter studyKazuya Motomura
Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan
Cancer 117:1721-30. 2011..The aim of the current study was to catalog genomic and epigenomic abnormalities in newly diagnosed glioblastoma patients and determine the correlation among clinical, genetic, and epigenetic profiles and clinical outcome... 
[Targeting epigenetics plasticity as a novel target for human neoplasia]Keiko Shinjo
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Chikusa ku, Nagoya, Japan
Gan To Kagaku Ryoho 37:1654-8. 2010..The reversible nature of epigenetic changes has led to the emergence of the field of epigenetic therapy, which may lead to potent and promising cancer treatment...- [Epigenetic analyses of brain tumor stem cells]Atsushi Natsume
Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya, Aichi 466 8550, Japan
Brain Nerve 61:791-8. 2009..In addition, we considered the prospects for developing epigenetic therapies... - Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signalingKanako Yuki
Center for Genetic and Regenerative Medicine, Nagoya University Hospital, Nagoya, Japan
Cancer Lett 284:71-9. 2009..Therefore, IFN may be a potential therapeutic agent for inducing the terminal differentiation of GICs... - Clinical implications of epigenetic alterations in human thoracic malignancies: epigenetic alterations in lung cancerKeiko Shinjo
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Chikusa ku, Nagoya, Japan
Methods Mol Biol 863:221-39. 2012..In this chapter, studies of epigenetic abnormality and its clinical implication in lung cancers are discussed... - Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cellsTakayuki Murata
Division of Virology, Aichi Cancer Center Research Institute, Kanokoden, Chikusa ku, Nagoya, Japan
J Virol 86:4752-61. 2012.... - Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancerHirotaka Osada
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
Cancer Res 68:1647-55. 2008.... - The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human gliomaAtsushi Natsume
Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan
Int J Cancer 122:2542-53. 2008..These results suggested that 5-aza-CdR induces the expression of epigenetically silenced CTAs in poorly immunogenic gliomas and thereby presents a new strategy for tumor immunotherapy targeting 5-aza-CdR-induced CTAs... - Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancersByonggu An
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Chikusa ku, Nagoya 464 8681, Japan
Int J Cancer 127:2095-105. 2010.... - RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell lineNaohito Sato
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
Int J Cancer 120:543-51. 2007..The present study demonstrates that RhoB expression is frequently downregulated in NSCLCs by multiple mechanisms, suggesting that RhoB is a candidate TSG for NSCLC... - Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in JapanYasuhiro Oki
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Cancer Sci 103:1839-47. 2012..In summary, decitabine was safe and demonstrated efficacy in Japanese patients with high-risk MDS. This trial was registered at ClinicalTrials.gov (NCT00796003)... - Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomasYutaka Kondo
Division of Molecular Oncology, Aichi Cancer Center Research Institute, Aichi, Japan
Hepatol Res 37:974-83. 2007..01). Conclusion: These data suggest that multiple epigenetic silencing mechanisms are inappropriately active in HCC cells... - Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancerYutaka Kondo
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
Mol Cell Biol 23:206-15. 2003..Our results suggest that reduced H3 Lys-4 methylation and increased H3 Lys-9 methylation play a critical role in the maintenance of promoter DNA methylation-associated gene silencing in colorectal cancer... - Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylationSatoshi Fujii
Department of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Hum Mol Genet 12:1791-800. 2003.... - Epigenetic changes in colorectal cancerYutaka Kondo
Department of Leukemia, University of Texas at M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Metastasis Rev 23:29-39. 2004..Understanding epigenetic alterations as a driving force in neoplasia opens new fields of research in epidemiology, risk assessment, and treatment in CRCs... - Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancersEmile M Youssef
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 64:2411-7. 2004..These findings indicate that silencing of TIG1 promoter by hypermethylation is common in human cancers and may contribute to the loss of retinoic acid responsiveness in some neoplastic cells... - Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylationYutaka Kondo
Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Proc Natl Acad Sci U S A 101:7398-403. 2004..This unbiased approach confirms the tight coupling between DNA methylation and histone modifications in cancer and could be used to probe gene silencing in nonneoplastic conditions as well... - MGMT promoter methylation and field defect in sporadic colorectal cancerLanlan Shen
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Natl Cancer Inst 97:1330-8. 2005..The DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) is frequently methylated in colorectal cancer. We hypothesized that MGMT methylation could be one of the mediators of field cancerization in the colon mucosa... - RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosisYanis A Boumber
Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030, USA
Cancer Res 67:1997-2005. 2007..In MDS, RIL methylation is a marker of adverse prognosis independent of chromosome 5 and 7 deletions. Our data suggest that RIL is a good candidate TSG silenced by hypermethylation in cancer... - Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinomaYutaka Suehiro
Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Clin Cancer Res 14:2560-9. 2008.... - PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APLYoko Tabe
Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cancer Biol Ther 6:1967-77. 2007..In summary, these results provide rationale for the combined targeting of RAR and PPARgamma nuclear receptors in the therapy of APL... - Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylationYutaka Kondo
Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
Nat Genet 40:741-50. 2008..These data establish EZH2-mediated H3K27triM as a mechanism of tumor-suppressor gene silencing in cancer that is potentially independent of promoter DNA methylation... - Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panelLanlan Shen
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 67:11335-43. 2007..Our results confirm that epigenetic profiles are useful in identifying molecular mediators for cancer drug sensitivity (pharmaco-epigenomics)... - Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancerLanlan Shen
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030
Proc Natl Acad Sci U S A 104:18654-9. 2007..Together, our integrated genetic and epigenetic analysis reveals that colon cancers correspond to three molecularly distinct subclasses of disease... - Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promotersLanlan Shen
Department of Leukemia, The University of Texas at M D Anderson Cancer Center, Houston, Texas, USA
PLoS Genet 3:2023-36. 2007.... - PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancerYoshiyuki Watanabe
Department of Molecular Biology, Cancer Research Institute, Sapporo Medical University, Sapporo, Japan
Clin Cancer Res 13:4786-94. 2007..The aim of the present study was to begin to examine the involvement of epigenetic alteration of PRDM expression in gastric and colorectal cancer... - A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elementsAllen S Yang
Department of Leukemia, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Nucleic Acids Res 32:e38. 2004..This method can be used as a surrogate marker of genome-wide methylation changes. In addition, it is less labor intensive and requires less DNA than previous methods of assessing global DNA methylation... - Enrichment for histone H3 lysine 9 methylation at Alu repeats in human cellsYutaka Kondo
Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
J Biol Chem 278:27658-62. 2003..Thus H3-Lys9 methylation is enriched at human repetitive elements, particularly Alu elements, and may play a role in the suppression of recombination by these elements... - P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53Lanlan Shen
Department of Leukemia, The University of Texas at M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Gastroenterology 124:626-33. 2003..The results provide a possible explanation for the paucity of p53 mutations in colon cancers with microsatellite instability... - Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemiaLanlan Shen
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 101:4131-6. 2003..02). Our results indicate that p57KIP2 is frequently methylated in adult patients with ALL, and that inactivation of a pathway composed of p73, p15, and p57KIP2 predicts for poor prognosis in Ph-negative patients... - Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemiaLanlan Shen
Blood 100:3432-3; author reply 3433-4. 2002 - PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoterYoko Tabe
Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Unit 448, Houston, TX 77030, USA
Ann Hematol 85:689-704. 2006..These results demonstrate that oncogenic PML-RARalpha and AML1-ETO translocations are rarely associated with RARbeta2 promoter methylation in primary AML samples... - An Sp1/Sp3 binding polymorphism confers methylation protectionYanis A Boumber
Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, Texas, United States of America
PLoS Genet 4:e1000162. 2008..Our finding demonstrates that, in some genes, hypermethylation in cancer is dictated by protein-DNA interactions at the promoters and provides a novel mechanism by which genetic polymorphisms can influence an epigenetic state...